CA2936550C - Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators - Google Patents
Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators Download PDFInfo
- Publication number
- CA2936550C CA2936550C CA2936550A CA2936550A CA2936550C CA 2936550 C CA2936550 C CA 2936550C CA 2936550 A CA2936550 A CA 2936550A CA 2936550 A CA2936550 A CA 2936550A CA 2936550 C CA2936550 C CA 2936550C
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- alkyl
- carbonitrile
- pheny1
- hexahydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931291P | 2014-01-24 | 2014-01-24 | |
| US61/931,291 | 2014-01-24 | ||
| PCT/US2015/012579 WO2015112792A1 (en) | 2014-01-24 | 2015-01-23 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2936550A1 CA2936550A1 (en) | 2015-07-30 |
| CA2936550C true CA2936550C (en) | 2022-07-26 |
Family
ID=52484552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2936550A Active CA2936550C (en) | 2014-01-24 | 2015-01-23 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9464082B2 (enExample) |
| EP (1) | EP3097089B1 (enExample) |
| JP (1) | JP6530758B2 (enExample) |
| CN (1) | CN107074801B (enExample) |
| CA (1) | CA2936550C (enExample) |
| MX (1) | MX372772B (enExample) |
| TW (1) | TWI670263B (enExample) |
| WO (1) | WO2015112792A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| EP2841445B1 (en) | 2012-04-27 | 2017-06-14 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| AU2016219109B2 (en) * | 2015-02-12 | 2020-05-14 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| BR112019010511A2 (pt) | 2016-11-23 | 2019-09-17 | Bayer Ag | derivados de heterociclo bicíclico fundido como pesticidas |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11993574B2 (en) * | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| US20250025465A1 (en) * | 2021-11-17 | 2025-01-23 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| JP2005507892A (ja) * | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレーション | 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物 |
| AU2011240690C1 (en) | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| ES2653717T3 (es) | 2010-12-17 | 2018-02-08 | Reata Pharmaceuticals, Inc. | Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación |
-
2015
- 2015-01-23 WO PCT/US2015/012579 patent/WO2015112792A1/en not_active Ceased
- 2015-01-23 MX MX2016009589A patent/MX372772B/es active IP Right Grant
- 2015-01-23 JP JP2016548158A patent/JP6530758B2/ja active Active
- 2015-01-23 CA CA2936550A patent/CA2936550C/en active Active
- 2015-01-23 EP EP15705409.9A patent/EP3097089B1/en active Active
- 2015-01-23 US US14/604,129 patent/US9464082B2/en active Active
- 2015-01-23 TW TW104102426A patent/TWI670263B/zh active
- 2015-01-23 CN CN201580015069.4A patent/CN107074801B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015112792A1 (en) | 2015-07-30 |
| EP3097089A1 (en) | 2016-11-30 |
| TWI670263B (zh) | 2019-09-01 |
| US20150225397A1 (en) | 2015-08-13 |
| TW201605808A (zh) | 2016-02-16 |
| JP2017503840A (ja) | 2017-02-02 |
| EP3097089B1 (en) | 2021-02-24 |
| US9464082B2 (en) | 2016-10-11 |
| CN107074801B (zh) | 2021-11-05 |
| MX372772B (es) | 2020-06-29 |
| JP6530758B2 (ja) | 2019-06-12 |
| CA2936550A1 (en) | 2015-07-30 |
| CN107074801A (zh) | 2017-08-18 |
| MX2016009589A (es) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9464082B2 (en) | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| EP2892910B1 (en) | Glycyrrhetinic acid derivatives with anti-inflammatory activity | |
| CA2965981C (en) | Substituted chromanes and method of use | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| EP2922840B1 (en) | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | |
| CA2822071C (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| JP6139789B2 (ja) | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 | |
| WO2021150806A1 (en) | Heterocyclic compounds as anti-viral agents | |
| CA2956465A1 (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
| MX2014014658A (es) | Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos. | |
| CA2694284A1 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
| JP2012529525A (ja) | ホスファチジルイノシトール３−キナーゼの阻害薬 | |
| EP3426244A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| CA3174982A1 (en) | Rsv inhibiting 3-substituted quinoline and cinnoline derivatives | |
| CA3173354A1 (en) | A 2,3-dihydrofuro[2,3-c]pyridine-3-carboxamide compound and its antiviral use | |
| KR20240121746A (ko) | 테트라하이드로피리다진, 이를 포함하는 조성물, 및 이의 용도 | |
| AU2010216219A1 (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | |
| JP7182548B2 (ja) | アザインデノイソキノリン化合物およびその使用 | |
| EP4423067A1 (en) | Sarm1 modulators, preparations, and uses thereof | |
| CA3240538A1 (en) | Oxer1 antagonists and uses thereof | |
| WO2011041634A1 (en) | Pyrazole inhibitors of phosphatidylinositol 3-kinase | |
| WO2022010882A1 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors | |
| WO2020210246A1 (en) | Heterocyclic compounds as rsv inhibitors | |
| HK1133873A (en) | 5-(2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase | |
| HK1196355A (en) | Compounds useful as inhibitors of choline kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200122 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 |